Arbutus Biopharma Corporation
ABUS
$3.59
$0.010.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.25M | -76.57M | -69.92M | -76.70M | -77.09M |
| Total Depreciation and Amortization | 1.01M | 1.36M | 1.38M | 1.41M | 1.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.75M | 10.97M | 6.52M | 4.58M | 4.77M |
| Change in Net Operating Assets | -15.70M | 5.30M | -2.83M | -1.11M | -2.00M |
| Cash from Operations | -60.19M | -58.95M | -64.85M | -71.83M | -72.88M |
| Capital Expenditure | -86.00K | -87.00K | -182.00K | -96.00K | -128.00K |
| Sale of Property, Plant, and Equipment | 9.00K | -- | -- | 0.00 | 20.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.46M | 22.69M | 23.13M | 31.86M | 54.29M |
| Cash from Investing | 28.39M | 22.60M | 22.95M | 31.76M | 54.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.43M | 30.35M | 52.00M | 54.38M | 54.29M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.43M | 30.35M | 52.00M | 54.38M | 54.29M |
| Foreign Exchange rate Adjustments | -3.00K | -32.00K | -49.00K | -2.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.38M | -6.03M | 10.05M | 14.32M | 35.59M |